Navigation Links
Celiac disease vaccine shows promising results in Phase I trial
Date:5/9/2011

The world's first potential vaccine for coeliac disease has shown promising results for treating coeliac disease in a Phase I clinical trial and is expected to move to Phase II trials within the next year.

The Phase I trial undertaken in Melbourne, Australia, evaluated the safety, tolerability and bioactivity of the vaccine Nexvax2, which has been developed for coeliac disease. Coeliac disease is an autoimmune disease caused by an immune reaction to the gluten protein found in wheat, rye and barley.

The three peptides on which the vaccine is based were identified by Dr Bob Anderson from the Walter and Eliza Hall Institute's Immunology division. The vaccine is being further developed by US biotechnology company ImmusanT, of which Dr Anderson is Chief Scientific and Medical Officer. Dr Anderson presented the Phase I trial results on Sunday at the Digestive Disease Week symposium in Chicago, Illinois, US.

"Nexvax2 aims to desensitise patients to the three specific peptides in gluten that we have previously identified as 'toxic' to people with coeliac disease," Dr Anderson said. "Our Phase I study showed that Nexvax2 was safe to use and well tolerated, and importantly, that it had the desired biological response in patients with coeliac disease."

Up to one per cent of the global population is affected by coeliac disease, which is currently only treatable by eliminating gluten from the diet. In people with coeliac disease, immune cells react to gluten and trigger an immune response that damages the lining of the small intestine and inhibits its ability to absorb nutrients from food.

Dr Anderson said the vaccine would be suitable for treating the approximately 90 per cent of coeliac disease patients with the DQ2 genetic form of disease.

"In our Phase I trial, we saw a Nexvax2-specific T-cell response that confirms the desired bioactivity in HLA-DQ2 genotype patients," Dr Anderson said. "We expect the vaccine to
'/>"/>

Contact: Ms Penny Fannin
fannin@wehi.edu.au
61-393-452-345
Walter and Eliza Hall Institute
Source:Eurekalert  

Page: 1 2

Related biology news :

1. New and improved gluten-free foods developed for patients with celiac disease
2. New book from the AGA empowers celiac disease patients to get healthy
3. UM School of Medicine Center for Celiac Research finds rate of celiac disease is growing
4. Quest for genes involved in celiac disease
5. Hidden infections crucial to understanding, controlling disease outbreaks
6. Iron-moving malfunction may underlie neurodegenerative diseases, aging
7. LIAI launches new division to look at novel approaches to heart disease and inflammation
8. Sirtris review of sirtuin therapeutics for diseases of aging in Nature Reviews Drug Discovery
9. World leaders in infectious diseases convene to discuss emerging global viruses
10. Form of Crohns disease traced to disabled gut cells
11. LSUHSC awarded patent for compound inhibiting cancer and other diseases
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Celiac disease vaccine shows promising results in Phase I trial
(Date:10/29/2014)... 29, 2014, Beaverton, OR) New research presented ... International Conference in Houston, TX showed for the ... HPV infection in women using a readily available ... study, presented by Dr. Judith A. Smith, Pharm.D., ... and Reproductive Sciences at The University of Texas ...
(Date:10/29/2014)... both genetic and environmental, have been blamed for ... Some, such as a family history of schizophrenia, ... Toxoplasma gondii , a parasite transmitted by ... viewed with skepticism. , A new study by ... at the University of Pennsylvania,s School of Veterinary ...
(Date:10/29/2014)... number of chemicals from household and industrial products are ... bodies. But for most of them, scientists have yet ... taken the first step toward doing that by estimating ... new method is published in the ACS journal ... and colleagues note that the risks to human health ...
Breaking Biology News(10 mins):HPV infections in women eradicated by AHCC, Japanese mushroom extract 2Penn vet professor investigates parasite-schizophrenia connection 2Penn vet professor investigates parasite-schizophrenia connection 3
... skunk, the reaction usually is "Eww," but when they ... think "Aww." Why some animals use noxious scents ... against predators is the question that biologists Tim Caro ... of California State University, Long Beach and sought ...
... and his colleagues have found a new application for ... help solve problems in biology. Specifically, the team ... on something known as epigenetic memory -- how an ... condition, such as quality of nutrition or temperature. ...
... important in a biology lab as a gym. Shape is ... cells grown to repair or replace damaged tissue in the ... "shape up," researchers at the National Institute of Standards and ... and more importantly, classify, the shapes cells tend to take ...
Cached Biology News:Social or stinky? New study reveals how animal defenses evolve 2New application of physics tools used in biology 2Shape-sifting: NIST categorizes bio scaffolds by characteristic cell shapes 2
(Date:10/31/2014)... Burlington, MA (PRWEB) October 31, 2014 ... is hosting a free learning webinar to introduce its ... managers, standards directors and biostatisticians. , Launched in September, ... the company's suite of clinical trial automation tools. For ... in a web browser. And by introducing Formations – ...
(Date:10/31/2014)... Brady (NYSE:BRC), a global leader in product ... video testimonial on the effectiveness of its FreezerBondz™ ... at the BloodCenter of Wisconsin discusses the challenges she ... of thousands of samples, and how the durability of ... we design our label materials with the harsh conditions ...
(Date:10/31/2014)... , Oct. 31, 2014  Tavistock Development ... by Tavistock Group, celebrated the groundbreaking of the ... City. The 92,000-square-foot, three-story facility ... Central Florida designed specifically for life ... the heart of the 650-acre Lake Nona Medical ...
(Date:10/30/2014)... 2014 Investor-Edge has initiated coverage ... ONVO), Medivation Inc. (NASDAQ: MDVN ), Pharmacyclics ... (NYSE MKT: SYN), and Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD). ... at: http://investor-edge.com/register . On Wednesday, October ... 0.33%, the Dow Jones Industrial Average declined 0.18%, to ...
Breaking Biology Technology:Formedix to Introduce "Revolutionary" Clinical Trial Automation Software with Learning Webinar 2Brady Debuts New Lab Label Testimonial Video 2GuideWell Innovation Center Groundbreaking Hosted by Tavistock Development Company at Lake Nona Medical City 2GuideWell Innovation Center Groundbreaking Hosted by Tavistock Development Company at Lake Nona Medical City 3Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 2Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 3Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 4Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 5
... Simcere,Pharmaceutical Group (NYSE: SCR ), a ... manufacturer of the patented,anti-cancer biotech product Endu in ... one of its existing shareholders, New Good Management,Limited, ... 15,individuals, including certain senior management of Simcere Pharmaceutical,has ...
... Basis, Proprietary MicroRNAs for Research Applications ... has Access to a Full Range of ... on These MicroRNAs, REHOVOT, Israel and JERSEY CITY, ... ), a leading,developer of microRNA-based diagnostics and therapeutics, announced ...
... System Combines Clinical Benefits of Dual Wavelengths Through ... Time While Providing a Uniform, Safe and Effective ... Treatment - New Offering Signals Company,s Expansion into International Laser ... Lipolysis Market, WESTFORD, Mass., April 28 Cynosure, ...
Cached Biology Technology:Simcere Pharmaceutical Group Reports Proposed Private Sale of Ordinary Shares by Existing Shareholder 2Simcere Pharmaceutical Group Reports Proposed Private Sale of Ordinary Shares by Existing Shareholder 3Rosetta Genomics Announces Expansion of its MicroRNA Intellectual Property Estate 2Rosetta Genomics Announces Expansion of its MicroRNA Intellectual Property Estate 3Rosetta Genomics Announces Expansion of its MicroRNA Intellectual Property Estate 4Cynosure Introduces Smartlipo MPX(TM) Dual Wavelength Workstation for LaserBodySculpting(SM) 2Cynosure Introduces Smartlipo MPX(TM) Dual Wavelength Workstation for LaserBodySculpting(SM) 3Cynosure Introduces Smartlipo MPX(TM) Dual Wavelength Workstation for LaserBodySculpting(SM) 4Cynosure Introduces Smartlipo MPX(TM) Dual Wavelength Workstation for LaserBodySculpting(SM) 5
... The new D-LUX Detection Platform ... to provide the most sensitive, specific, ... qPCR. Invitrogens D-LUX Detection Platform offers ... equal to TaqMan probes, high signal/background ...
Provides continuous mixing action. For use with tubes, vials, and other containers...
... is aseptically collected via cardiac puncture from 3 ... mixed sex). It is then centrifuged and frozen ... filtered and bottled at 4C then stored at ... HAVE ALWAYS USED PEL-FREEZ COMPLEMENT, YOU CAN NOW ...
Modified and insect cell culture tested....
Biology Products: